ArticleCase reports in medicine2025
Beating the Odds: A Successful Pregnancy in a Patient With ALK-Rearranged Lung Cancer on Alectinib.
Article in Case reports in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The management of oncogene-driven non-small cell lung cancer (NSCLC) during pregnancy presents unique challenges due to limited safety data on targeted therapies. Anaplastic lymphoma kinase (ALK)-rearranged NSCLC is a rare but increasingly recognized entity in young women, including during pregnancy. Here, we report the case of a 37-year-old woman diagnosed with metastatic ALK-rearranged NSCLC during her first pregnancy, who was commenced on alectinib. Following this, she had a successful second pregnancy whilst being treated with alectinib (withheld during weeks 6-10 of gestation to avoid the critical period of organogenesis). Both pregnancies resulted in healthy infants with no complications or evidence of developmental delays. This case highlights the importance of a multidisciplinary approach involving oncology, maternal-fetal medicine, clinical genetics, obstetrics medicine, and obstetrics to balance maternal cancer control and fetal health. While preclinical studies of alectinib suggest teratogenic risks, this and other reported cases demonstrate its potential for safe use during pregnancy with careful planning. Pathological examination of the placenta in our case revealed no malignant cells, and maternal disease remained controlled. As targeted therapies extend survival in advanced NSCLC, more patients may contemplate pregnancy, emphasizing the need for robust evidence to guide treatment decisions. This case contributes to the growing body of evidence supporting the feasibility of managing pregnancy in patients with ALK-rearranged NSCLC using targeted therapies like alectinib, while underscoring the importance of long-term follow-up for the exposed offspring.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.